Slovenia is positioning itself to become a key European hub for biotechnology and pharmaceuticals, following the signing of a letter of intent between the government and the newly-established Biotech Hills institute. This strategic partnership aims to make Slovenia the most attractive destination in Europe for research, development, manufacturing, and investment in the biotech sector.

The agreement, signed on September 2nd during the Bled Strategic Forum by Economy Minister Matjaž Han and Robert Ljoljo, president of Biotech Hills' council and Sandoz Slovenia, marks a significant step in creating a robust biotechnology ecosystem in the country. The partnership is focused on enhancing Slovenia's reputation as a global meeting point for biotech and pharmaceutical innovation, attracting top talent and investment from around the world.

Minister Han emphasized the importance of this collaboration, stating that Slovenia is on track to become a major player in the global biotech industry. Ljoljo added that by 2030, the initiative could generate an additional €100 million in turnover, create up to 1,000 high-skilled jobs, and increase the biotech sector’s contribution to Slovenia's GDP from 6% to 9%.

The Biotech Hills accelerator, launched by partners including pharmaceutical giants Novartis and Lek, aims to foster an innovation-friendly environment through collaboration, strategic planning, and legislative support. The accelerator’s mission is to attract start-ups, SMEs, and large corporations to invest in R&D and production in Slovenia, bolstering both the national and European economy.

With a vision to grow the biotech sector and improve European economic resilience, the Slovenian government’s partnership with Biotech Hills sets the stage for significant growth and innovation, making Slovenia a prime destination for biotech investment and development.